Kyverna Therapeutics, Inc. Cash and Cash Equivalents
Kyverna Therapeutics, Inc. (KYTX) had Cash and Cash Equivalents of $31.81 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-11
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $31.81M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $32.19M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $124.09M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $34.16M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $31.81M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $32.19M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $124.09M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $34.16M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $53.44M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $56.87M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $96.62M 10-K · filed 2026-03-26 |
| 2024-09-30 | $104.66M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $131.62M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $224.29M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $34.65M 10-K · filed 2025-03-27 |
| 2023-09-30 | $22.97M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $53.43M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $39.79M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |